Articles with public access mandates - Aung NaingLearn more
Not available anywhere: 14
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ...
Nature medicine 29 (1), 115-126, 2023
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors
DS Hong, H Henary, GS Falchook, A Naing, S Fu, S Moulder, JJ Wheler, ...
Investigational new drugs 32, 1204-1212, 2014
Mandates: US National Institutes of Health
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma
DC Smith, M Kroiss, E Kebebew, MA Habra, R Chugh, BJ Schneider, ...
Investigational new drugs 38, 1421-1429, 2020
Mandates: US National Institutes of Health
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial
AW Hahn, J Chahoud, MT Campbell, DD Karp, J Wang, B Stephen, ...
Investigational new drugs 39, 1405-1410, 2021
Mandates: US National Institutes of Health
Interleukin-10 in cancer immunotherapy: from bench to bedside
MA Salkeni, A Naing
Trends in Cancer 9 (9), 716-725, 2023
Mandates: US National Institutes of Health
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
MA Bilen, A Patel, KR Hess, J Munoz, NL Busaidy, JJ Wheler, F Janku, ...
Cancer chemotherapy and pharmacology 78, 167-171, 2016
Mandates: US National Institutes of Health
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer
R Said, Y Ye, DS Hong, A Naing, G Falchook, S Fu, JJ Wheler, ...
Cancer chemotherapy and pharmacology 77, 575-581, 2016
Mandates: US National Institutes of Health
Outcomes of patients≥ 65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center
IM Subbiah, JJ Wheler, KR Hess, DS Hong, A Naing, S Fu, R Kurzrock, ...
International journal of cancer 140 (1), 208-215, 2017
Mandates: US National Institutes of Health
Pembrolizumab in patients with refractory cutaneous squamous cell carcinoma: a phase II trial
R Ferrarotto, LG Sousa, Y Qing, D Kaya, B Stephen, D Jain, D Bell, S Pant, ...
Advances in Therapy 38 (8), 4581-4591, 2021
Mandates: US National Institutes of Health
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and …
E Fountzilas, E Krishnan, F Janku, S Fu, DD Karp, A Naing, V Subbiah, ...
Cancer chemotherapy and pharmacology 82, 877-885, 2018
Mandates: US National Institutes of Health
Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors
M Yibirin, K Mustafayev, J Hosry, P Pundhir, J Klingen, EY Guevara, ...
Official journal of the American College of Gastroenterology| ACG, 10.14309, 2022
Mandates: US National Institutes of Health
Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The MD Anderson Cancer Center experience.
JJ Wheler, AM Tsimberidou, S Wen, A Naing, DS Hong, GS Falchook, ...
Journal of Clinical Oncology 28 (15_suppl), 2604-2604, 2010
Mandates: US National Institutes of Health
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab in combination with escalating doses of oral …
DW Davis, W Liu, D Mittelman, R Kurzrock, A Naing, J Wheler, L Ricks, ...
J Clin Oncol 27 (15), 2009
Mandates: US National Institutes of Health
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials
O Alhalabi, AW Hahn, P Msaouel, F Meric-Bernstam, N Wilson, A Naing, ...
Clinical Genitourinary Cancer 20 (1), e16-e24, 2022
Mandates: US Department of Defense, US National Institutes of Health
Available somewhere: 232
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ...
Journal of Clinical Oncology 36 (17), 1714-1768, 2018
Mandates: US National Institutes of Health
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ...
Journal of Clinical Oncology 39 (36), 4073-4126, 2021
Mandates: US National Institutes of Health
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ...
Clinical cancer research 18 (22), 6373-6383, 2012
Mandates: US National Institutes of Health
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ...
Journal of clinical oncology 30 (8), 777-782, 2012
Mandates: US National Institutes of Health
A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer
PA Ott, S Hu-Lieskovan, B Chmielowski, R Govindan, A Naing, ...
Cell 183 (2), 347-362. e24, 2020
Mandates: US National Institutes of Health
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
F Janku, AM Tsimberidou, I Garrido-Laguna, X Wang, R Luthra, DS Hong, ...
Molecular cancer therapeutics 10 (3), 558-565, 2011
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program